{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:09:02Z","timestamp":1772208542302,"version":"3.50.1"},"reference-count":71,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008110","name":"Boler-Parseghian Center for Rare and Neglected Diseases","doi-asserted-by":"publisher","award":["Pilot Study Award"],"award-info":[{"award-number":["Pilot Study Award"]}],"id":[{"id":"10.13039\/100008110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Von Hippel-Lindau disease (VHL) is an autosomal dominant rare disease that causes the formation of angiogenic tumors. When functional, pVHL acts as an E3 ubiquitin ligase that negatively regulates hypoxia inducible factor (HIF). Genetic mutations that perturb the structure of pVHL result in dysregulation of HIF, causing a wide array of tumor pathologies including retinal angioma, pheochromocytoma, central nervous system hemangioblastoma, and clear cell renal carcinoma. These VHL-related cancers occur throughout the lifetime of the patient, requiring frequent intervention procedures, such as surgery, to remove the tumors. Although VHL is classified as a rare disease (1 in 39,000 to 1 in 91,000 affected) there is a large heterogeneity in genetic mutations listed for observed pathologies. Understanding how these specific mutations correlate with the myriad of observed pathologies for VHL could provide clinicians insight into the potential severity and onset of disease. Using a select set of 285 ClinVar mutations in VHL, we developed a multiparametric scoring algorithm to evaluate the overall clinical severity of missense mutations in pVHL. The mutations were assessed according to eight weighted parameters as a comprehensive evaluation of protein misfolding and malfunction. Higher mutation scores were strongly associated with pathogenicity. Our approach establishes a novel\n                    <jats:italic>in silico<\/jats:italic>\n                    method by which VHL-specific mutations can be assessed for their severity and effect on the biophysical functions of the VHL protein.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0234100","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T13:48:59Z","timestamp":1604584139000},"page":"e0234100","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Algorithmic assessment of missense mutation severity in the Von-Hippel Lindau protein"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9029-5150","authenticated-orcid":true,"given":"Francisco R.","family":"Fields","sequence":"first","affiliation":[]},{"given":"Niraja","family":"Suresh","sequence":"additional","affiliation":[]},{"given":"Morgan","family":"Hiller","sequence":"additional","affiliation":[]},{"given":"Stefan D.","family":"Freed","sequence":"additional","affiliation":[]},{"given":"Kasturi","family":"Haldar","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9305-2050","authenticated-orcid":true,"given":"Shaun W.","family":"Lee","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"pone.0234100.ref001","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrc3844","article-title":"VHL, the story of a tumour suppressor gene","volume":"15","author":"L Gossage","year":"2015","journal-title":"Nature Reviews Cancer"},{"issue":"33","key":"pone.0234100.ref002","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.2174\/138161209789649394","article-title":"The VHL Tumor Suppressor: Master Regulator of HIF","volume":"15","author":"V Haase","year":"2009","journal-title":"Curr Pharm Des"},{"issue":"5112","key":"pone.0234100.ref003","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"F Latif","year":"1993","journal-title":"Science (80-)"},{"issue":"14","key":"pone.0234100.ref004","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/jnci\/81.14.1097","article-title":"Specific genetic change in tumors associated with von hippel-lindau disease","volume":"81","author":"K Tory","year":"1989","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"pone.0234100.ref005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00218913","article-title":"Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours","volume":"93","author":"PA Crossey","year":"1994","journal-title":"Hum Genet"},{"issue":"20","key":"pone.0234100.ref006","doi-asserted-by":"crossref","first-page":"11661","DOI":"10.1073\/pnas.95.20.11661","article-title":"pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation","volume":"95","author":"O Iliopoulos","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"pone.0234100.ref007","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/sj.onc.1202473","article-title":"Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity","volume":"18","author":"C Blankenship","year":"1999","journal-title":"Oncogene"},{"key":"pone.0234100.ref008","article-title":"VHLdb: A database of von Hippel-Lindau protein interactors and mutations OPEN","author":"F Tabaro","year":"2016","journal-title":"Nat Publ Gr"},{"issue":"6","key":"pone.0234100.ref009","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.str.2017.04.009","article-title":"Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase Complex","volume":"25","author":"TAF Cardote","year":"2017","journal-title":"Structure"},{"issue":"11","key":"pone.0234100.ref010","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1172\/JCI8161","article-title":"Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein","volume":"104","author":"M Ohh","year":"1999","journal-title":"J Clin Invest"},{"issue":"5413","key":"pone.0234100.ref011","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1126\/science.284.5413.455","article-title":"Structure of the VHL-elonginC-elonginB complex: Implications for VHL tumor suppressor function","volume":"284","author":"CE Stebbins","year":"1999","journal-title":"Science"},{"issue":"September","key":"pone.0234100.ref012","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.7660130","article-title":"Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C","volume":"269","author":"A Kibel","year":"1995","journal-title":"Science (80-)"},{"issue":"7","key":"pone.0234100.ref013","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/35017054","article-title":"Ubiquitination of hypoxia-inducible factor requires direct binding to the \u03b2-domain of the von Hippel\u2014Lindau protein","volume":"2","author":"M Ohh","year":"2000","journal-title":"Nat Cell Biol"},{"issue":"22","key":"pone.0234100.ref014","doi-asserted-by":"crossref","first-page":"12436","DOI":"10.1073\/pnas.96.22.12436","article-title":"Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex","volume":"96","author":"K Iwai","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"pone.0234100.ref015","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1101\/gad.13.14.1822","article-title":"The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity","volume":"13","author":"J Lisztwan","year":"1999","journal-title":"Genes Dev"},{"issue":"6733","key":"pone.0234100.ref016","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"PH Maxwell","year":"1999","journal-title":"Nature"},{"issue":"1","key":"pone.0234100.ref017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-05554-1","article-title":"HIF-2\u03b1-pVHL complex reveals broad genotype-phenotype correlations in HIF-2\u03b1-driven disease","volume":"9","author":"D Tarade","year":"2018","journal-title":"Nat Commun"},{"issue":"6892","key":"pone.0234100.ref018","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature00767","article-title":"Structural basis for the recognition of hydroxyproline in HIF-1\u03b1 by pVHL","volume":"417","author":"WC Hon","year":"2002","journal-title":"Nature"},{"issue":"3","key":"pone.0234100.ref019","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/sj.onc.1209062","article-title":"Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1\u03b1 interactions","volume":"25","author":"K Knauth","year":"2006","journal-title":"Oncogene"},{"issue":"16","key":"pone.0234100.ref020","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1158\/0008-5472.CAN-11-0757","article-title":"VHL gene mutations and their effects on hypoxia inducible factor HIF\u03b1: identification of potential driver and passenger mutations","volume":"71","author":"MP Rechsteiner","year":"2011","journal-title":"Cancer Res"},{"issue":"8","key":"pone.0234100.ref021","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/sj.bjc.6605298","article-title":"Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma","volume":"101","author":"JJ Patard","year":"2009","journal-title":"Br J Cancer"},{"issue":"9374","key":"pone.0234100.ref022","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von Hippel-Lindau disease","volume":"361","author":"RR Lonser","year":"2003","journal-title":"Lancet (London, England)"},{"issue":"3","key":"pone.0234100.ref023","first-page":"5461","article-title":"Von Hippel-Lindau disease: Diagnosis and factors influencing disease outcome","volume":"65","author":"MLM Binderup","year":"2018","journal-title":"Dan Med J"},{"issue":"1","key":"pone.0234100.ref024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/jmedgenet-2016-104058","article-title":"Survival and causes of death in patients with von Hippel-Lindau disease","volume":"54","author":"MLM Binderup","year":"2017","journal-title":"J Med Genet"},{"issue":"2","key":"pone.0234100.ref025","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.20385","article-title":"Genotype-phenotype correlations in von Hippel-Lindau disease","volume":"28","author":"RO Kai","year":"2007","journal-title":"Hum Mutat"},{"issue":"24","key":"pone.0234100.ref026","doi-asserted-by":"crossref","first-page":"38456","DOI":"10.18632\/oncotarget.16594","article-title":"Genotype-phenotype correlations in Chinese von Hippel-Lindau disease patients","volume":"8","author":"S Peng","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"pone.0234100.ref027","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/humu.20082","article-title":"Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions","volume":"24","author":"C Gallou","year":"2004","journal-title":"Hum Mutat"},{"issue":"10","key":"pone.0234100.ref028","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/gim.2017.261","article-title":"Genotype and phenotype correlation in von Hippel\u2013Lindau disease based on alteration of the HIF-\u03b1 binding site in VHL protein","volume":"20","author":"SJ Liu","year":"2018","journal-title":"Genet Med"},{"issue":"1","key":"pone.0234100.ref029","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2688-0","article-title":"Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: Hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance","volume":"16","author":"C Razafinjatovo","year":"2016","journal-title":"BMC Cancer"},{"issue":"D1","key":"pone.0234100.ref030","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: Improving access to variant interpretations and supporting evidence","volume":"46","author":"MJ Landrum","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"pone.0234100.ref031","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"S Richards","year":"2015","journal-title":"Genet Med"},{"issue":"3","key":"pone.0234100.ref032","doi-asserted-by":"crossref","first-page":"121511","DOI":"10.1371\/journal.pone.0121511","article-title":"A multiparametric computational algorithm for comprehensive assessment of genetic mutations in mucopolysaccharidosis type IIIA (Sanfilippo Syndrome)","volume":"10","author":"KG Ugrinov","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"pone.0234100.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006478","article-title":"Genotype-phenotype relations of the von hippel-lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors","volume":"15","author":"G Minervini","year":"2019","journal-title":"PLoS Comput Biol"},{"issue":"2","key":"pone.0234100.ref034","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.20385","article-title":"Genotype-phenotype correlations in von Hippel-Lindau disease","volume":"28","author":"RO Kai","year":"2007","journal-title":"Hum Mutat"},{"issue":"3","key":"pone.0234100.ref035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/humu.20082","article-title":"Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions","volume":"24","author":"C Gallou","year":"2004","journal-title":"Hum Mutat"},{"issue":"1999","key":"pone.0234100.ref036","first-page":"455","article-title":"Structure of the Complex: Implications for VHL Tumor Suppressor Function","volume":"455","author":"CE Stebbins","year":"2009","journal-title":"Science (80-)"},{"issue":"5574","key":"pone.0234100.ref037","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1126\/science.1073440","article-title":"Structure of an HIF-1\u03b1-pVHL complex: Hydroxyproline recognition in signaling","volume":"296","author":"JH Min","year":"2002","journal-title":"Science (80-)"},{"key":"pone.0234100.ref038","doi-asserted-by":"crossref","first-page":"5.8.1","DOI":"10.1002\/0471250953.bi0508s52","article-title":"Protein Structure and Function Prediction Using I-TASSER","volume":"52","author":"J Yang","year":"2015","journal-title":"Curr Protoc Bioinforma"},{"issue":"1","key":"pone.0234100.ref039","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1471-2105-8-65","article-title":"AGGRESCAN: A server for the prediction and evaluation of \u201chot spots\u201d of aggregation in polypeptides","volume":"8","author":"O Conchillo-Sol\u00e9","year":"2007","journal-title":"BMC Bioinformatics"},{"issue":"6892","key":"pone.0234100.ref040","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature00767","article-title":"Structural basis for the recognition of hydroxyproline in HIF-1\u03b1 by pVHL","volume":"417","author":"WC Hon","year":"2002","journal-title":"Nature"},{"key":"pone.0234100.ref041","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00018-009-0014-6","article-title":"Functional aspects of protein flexibility","volume":"66","author":"K Teilum","year":"2009","journal-title":"Cellular and Molecular Life Sciences. SP Birkh\u00e4user Verlag Basel"},{"key":"pone.0234100.ref042","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1096\/fasebj.9.9.7601338","article-title":"Proline motifs in peptides and their biological processing","volume":"9","author":"G Vanhoof","year":"1995","journal-title":"FASEB Journal"},{"issue":"1","key":"pone.0234100.ref043","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/10409239309082572","article-title":"Proline-dependent structural and biological properties of peptides and proteins","volume":"28","author":"A Yaron","year":"1993","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"1","key":"pone.0234100.ref044","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0006-3495(98)77529-0","article-title":"A Helix Propensity Scale Based on Experimental Studies of Peptides and Proteins","volume":"75","author":"C Nick Pace","year":"1998","journal-title":"Biophys J"},{"issue":"6464","key":"pone.0234100.ref045","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/367660a0","article-title":"Measurement of the \u03b2-sheet-forming propensities of amino acids","volume":"367","author":"DL Minor","year":"1994","journal-title":"Nature"},{"issue":"13","key":"pone.0234100.ref046","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/j.1742-4658.2012.08636.x","article-title":"Disulfide bonds: protein folding and subcellular protein trafficking","volume":"279","author":"M Narayan","year":"2012","journal-title":"FEBS J"},{"issue":"25","key":"pone.0234100.ref047","doi-asserted-by":"crossref","first-page":"10159","DOI":"10.1073\/pnas.0812414106","article-title":"Physicochemical principles that regulate the competition between functional and dysfunctional association of proteins","volume":"106","author":"S Pechmann","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"31","key":"pone.0234100.ref048","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1021\/bi00483a001","article-title":"Dominant Forces in Protein Folding","volume":"29","author":"KA Dill","year":"1990","journal-title":"Biochemistry"},{"key":"pone.0234100.ref049","first-page":"604","article-title":"Close-range electrostatic interactions in proteins","volume":"3","author":"S Kumar","year":"2002","journal-title":"ChemBioChem. John Wiley & Sons"},{"key":"pone.0234100.ref050","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1042\/BST0351569","article-title":"Prediction of protein stability upon point mutations","author":"MM Gromiha","year":"2007","journal-title":"Biochemical Society Transactions"},{"issue":"1","key":"pone.0234100.ref051","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1097-0134(20000701)40:1<58::AID-PROT80>3.0.CO;2-M","article-title":"Lower kinetic limit to protein thermal stability: A proposal regarding protein stability in vivo and its relation with misfolding diseases","volume":"40","author":"IM Plaza Del Pino","year":"2000","journal-title":"Proteins Struct Funct Genet"},{"issue":"10","key":"pone.0234100.ref052","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.tibs.2004.08.008","article-title":"Protein folding in the cell: Reshaping the folding funnel","volume":"29","author":"PL Clark","year":"2004","journal-title":"Trends Biochem Sci"},{"key":"pone.0234100.ref053","doi-asserted-by":"crossref","DOI":"10.1021\/bi00190a002","article-title":"Perspectives in Biochemistry Kinetics versus Thermodynamics in Protein Folding","volume":"33","author":"D Baker","year":"1994","journal-title":"Biochemistry"},{"key":"pone.0234100.ref054","first-page":"289","volume":"37","author":"KA Dill","year":"2008","journal-title":"The Protein Folding Problem"},{"key":"pone.0234100.ref055","article-title":"Protein kinetic stability","author":"JM Sanchez-Ruiz","year":"2010","journal-title":"Biophysical Chemistry"},{"issue":"2","key":"pone.0234100.ref056","doi-asserted-by":"crossref","first-page":"1004049","DOI":"10.1371\/journal.pcbi.1004049","article-title":"The Roles of Post-translational Modifications in the Context of Protein Interaction Networks","volume":"11","author":"G Duan","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"pone.0234100.ref057","author":"JX Huang","journal-title":"High throughput discovery of functionalaa protein modifications by Hotspot Thermal Profiling"},{"key":"pone.0234100.ref058","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2174\/0929867323666160118095620","article-title":"Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases","volume":"237","author":"S Basak","year":"2016","journal-title":"Curr Med Chem"},{"key":"pone.0234100.ref059","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jmb.2008.08.012","article-title":"Synonymous Mutations and Ribosome Stalling Can Lead to Altered Folding Pathways and Distinct Minima","volume":"383","author":"CJ Tsai","year":"2008","journal-title":"Journal of Molecular Biology. Academic Press"},{"issue":"1","key":"pone.0234100.ref060","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2164-11-118","article-title":"Increased incidence of rare codon clusters at 5\u2019 and 3\u2019 gene termini: Implications for function","volume":"11","author":"TF Clarke","year":"2010","journal-title":"BMC Genomics"},{"issue":"D1","key":"pone.0234100.ref061","doi-asserted-by":"crossref","first-page":"D184","DOI":"10.1093\/nar\/gkv1309","article-title":"GtRNAdb 2.0: An expanded database of transfer RNA genes identified in complete and draft genomes","volume":"44","author":"PP Chan","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"pone.0234100.ref062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep12605","article-title":"Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein","volume":"5","author":"G Minervini","year":"2015","journal-title":"Sci Rep"},{"key":"pone.0234100.ref063","author":"G Minervini","year":"2014","journal-title":"Design and Analysis of a Petri Net Model of the Von Hippel-Lindau (VHL) Tumor Suppressor Interaction Network"},{"issue":"13","key":"pone.0234100.ref064","first-page":"2881","article-title":"Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product","volume":"56","author":"H Tsuchiya","year":"1996","journal-title":"Cancer Res"},{"issue":"11","key":"pone.0234100.ref065","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.febslet.2012.04.032","article-title":"Systemic VHL gene functions and the VHL disease","volume":"586","author":"HL Bader","year":"2012","journal-title":"FEBS Lett"},{"issue":"5","key":"pone.0234100.ref066","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1172\/JCI73665","article-title":"Pharmacological HIF2\u03b1 inhibition improves VHL disease-associated phenotypes in zebrafish model","volume":"125","author":"AM Metelo","year":"2015","journal-title":"J Clin Invest"},{"key":"pone.0234100.ref067","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/sj.onc.1209062","article-title":"Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1a interactions","volume":"25","author":"K Knauth","year":"2006","journal-title":"Oncogene"},{"issue":"7","key":"pone.0234100.ref068","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/jmg.28.7.443","article-title":"Von Hippel-Lindau disease: A genetic study","volume":"28","author":"ER Maher","year":"1991","journal-title":"J Med Genet"},{"issue":"8749","key":"pone.0234100.ref069","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/0140-6736(91)91705-Y","article-title":"Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus","volume":"337","author":"HPH Neumann","year":"1991","journal-title":"Lancet"},{"issue":"9","key":"pone.0234100.ref070","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1210\/jc.2019-00235","article-title":"Synonymous but Not Silent: A Synonymous VHL Variant in Exon 2 Confers Susceptibility to Familial Pheochromocytoma and von Hippel-Lindau Disease","volume":"104","author":"SK Flores","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"pone.0234100.ref071","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2018-03-838235","article-title":"Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease","volume":"132","author":"M Lenglet","year":"2018","journal-title":"Blood"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T17:02:52Z","timestamp":1618246972000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234100"}},"subtitle":[],"editor":[{"given":"Ramin","family":"Massoumi","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":71,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0234100","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.20.106021","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]}}}